Modified-FOLFIRINOX in metastatic pancreatic cancer: A prospective study in Chinese population

Xiang Li, Tao Ma, Qi Zhang, Yi Gang Chen, Cheng Xiang Guo, Yi Nan Shen, Pei Wei Sun, Guo Gang Li, Shun Liang Gao, Ri Sheng Que, Jian Ying Lou, Ri Sheng Yu, Ying Yuan, Qi Chun Wei, Shu Mei Wei, Yun Zhang, Lei Zheng, Xue Li Bai, Ting Bo Liang

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


FOLFIRINOX chemotherapy has shown remarkable responses in patients with metastatic pancreatic cancer (MPC), and has significantly improved prognosis. However, FOLFIRINOX is currently not frequently applied in China because of its high incidence of adverse events, and there is no recognized optimization for this therapy in Chinese population. Modification of FOLFIRINOX may be better for its acceptance in China. In this study, we evaluated the efficacy and safety of modified-FOLFIRINOX in patients with MPC. A total of 62 MPC patients were treated with modified-FOLFIRINOX (no Fluorouracil bolus, 85% Oxaliplatin and 75% Irinotecan) between April 2014 and April 2017 in our institute. 40 of them were evaluated, with a response rate of 32.5% (13/40). The frequent grade 3/4 adverse events are neutropenia (29%) and alanine aminotransferase elevation (14.5%). No treatment-related death was observed. The median overall survival and median progression-free survival are 10.3 months and 7.0 months, respectively. In conclusion, modified-FOLFIRINOX had significantly improved tolerance with similar efficacy to FOLFIRINOX. These findings may provide evidence for the use of FOLFIRINOX in Chinese patients with MPC.

Original languageEnglish (US)
Pages (from-to)22-26
Number of pages5
JournalCancer Letters
StatePublished - Oct 10 2017


  • Chemotherapy
  • Dose modification
  • Metastatic
  • Pancreatic cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Modified-FOLFIRINOX in metastatic pancreatic cancer: A prospective study in Chinese population'. Together they form a unique fingerprint.

Cite this